UY31868A - Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia - Google Patents

Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia

Info

Publication number
UY31868A
UY31868A UY31868A UY31868A UY31868A UY 31868 A UY31868 A UY 31868A UY 31868 A UY31868 A UY 31868A UY 31868 A UY31868 A UY 31868A UY 31868 A UY31868 A UY 31868A
Authority
UY
Uruguay
Prior art keywords
derivatives
sulfamida
tafia inhibitors
inhibitors
macrocyclic urea
Prior art date
Application number
UY31868A
Other languages
English (en)
Spanish (es)
Inventor
Dr Michael Wagner
Dr Christopher Kallus
Dr Mark Broenstrup
Dr Andreas Evers
Dr Anja Globisch
Dr Herman Schreuder
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31868A publication Critical patent/UY31868A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY31868A 2008-06-06 2009-06-04 Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia UY31868A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06

Publications (1)

Publication Number Publication Date
UY31868A true UY31868A (es) 2010-01-05

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31868A UY31868A (es) 2008-06-06 2009-06-04 Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia

Country Status (35)

Country Link
US (5) US8580777B2 (fr)
EP (1) EP2300462B1 (fr)
JP (1) JP5531011B2 (fr)
KR (1) KR101673886B1 (fr)
CN (1) CN102056922B (fr)
AR (1) AR072007A1 (fr)
AU (1) AU2009254257B2 (fr)
BR (1) BRPI0913349A2 (fr)
CA (1) CA2726554C (fr)
CL (1) CL2009001358A1 (fr)
CO (1) CO6321271A2 (fr)
CR (1) CR11807A (fr)
CY (1) CY1115604T1 (fr)
DK (1) DK2300462T3 (fr)
DO (1) DOP2010000363A (fr)
EC (1) ECSP10010655A (fr)
ES (1) ES2494390T3 (fr)
HK (1) HK1152936A1 (fr)
HN (1) HN2010002558A (fr)
HR (1) HRP20140787T1 (fr)
IL (1) IL209772A (fr)
MA (1) MA32322B1 (fr)
MX (1) MX2010012793A (fr)
NI (1) NI201000203A (fr)
NZ (1) NZ589671A (fr)
PL (1) PL2300462T3 (fr)
PT (1) PT2300462E (fr)
RU (1) RU2502736C2 (fr)
SI (1) SI2300462T1 (fr)
SV (1) SV2010003747A (fr)
TW (1) TWI455928B (fr)
UA (1) UA104002C2 (fr)
UY (1) UY31868A (fr)
WO (1) WO2009146802A1 (fr)
ZA (1) ZA201007719B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ589671A (en) 2008-06-06 2012-03-30 Sanofi Aventis Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
CA2727925A1 (fr) 2008-06-23 2009-12-30 Astrazeneca Ab Nouveaux carboxamides heterocycliques utilises comme inhibiteurs de thrombine
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
JP5823066B2 (ja) * 2012-03-06 2015-11-25 ファイザー・インク 増殖性疾患の治療のための大環状誘導体
US9834527B2 (en) * 2013-06-10 2017-12-05 Sanofi Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
US6353023B1 (en) 1997-08-28 2002-03-05 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
WO2008067909A2 (fr) 2006-12-06 2008-06-12 Sanofi-Aventis Dérivés d'urée et de sulfamides utilisés comme inhibiteurs de tafi-a
NZ589671A (en) 2008-06-06 2012-03-30 Sanofi Aventis Macrocyclic urea and sulfamide derivatives as inhibitors of tafia

Also Published As

Publication number Publication date
RU2010154089A (ru) 2012-07-20
MX2010012793A (es) 2010-12-14
HN2010002558A (es) 2012-08-28
UA104002C2 (ru) 2013-12-25
SV2010003747A (es) 2011-03-15
US20140039011A1 (en) 2014-02-06
TW201008917A (en) 2010-03-01
NI201000203A (es) 2011-09-29
ES2494390T3 (es) 2014-09-15
US9126955B2 (en) 2015-09-08
NZ589671A (en) 2012-03-30
ECSP10010655A (es) 2011-01-31
AU2009254257B2 (en) 2013-11-21
AR072007A1 (es) 2010-07-28
CA2726554A1 (fr) 2009-12-10
US20140206760A1 (en) 2014-07-24
US20110178130A1 (en) 2011-07-21
TWI455928B (zh) 2014-10-11
US8722655B2 (en) 2014-05-13
MA32322B1 (fr) 2011-05-02
CN102056922B (zh) 2013-11-20
CY1115604T1 (el) 2017-01-04
CA2726554C (fr) 2015-02-24
CL2009001358A1 (es) 2009-11-27
CR11807A (es) 2011-02-16
DOP2010000363A (es) 2010-12-15
IL209772A (en) 2016-04-21
HK1152936A1 (en) 2012-03-16
EP2300462A1 (fr) 2011-03-30
EP2300462B1 (fr) 2014-05-21
US9309207B2 (en) 2016-04-12
RU2502736C2 (ru) 2013-12-27
JP2011521981A (ja) 2011-07-28
BRPI0913349A2 (pt) 2015-11-24
US20160024033A1 (en) 2016-01-28
KR101673886B1 (ko) 2016-11-08
IL209772A0 (en) 2011-02-28
HRP20140787T1 (hr) 2014-11-21
US8580777B2 (en) 2013-11-12
PL2300462T3 (pl) 2014-10-31
JP5531011B2 (ja) 2014-06-25
CO6321271A2 (es) 2011-09-20
SI2300462T1 (sl) 2014-09-30
CN102056922A (zh) 2011-05-11
WO2009146802A1 (fr) 2009-12-10
AU2009254257A1 (en) 2009-12-10
DK2300462T3 (da) 2014-08-18
US9688645B2 (en) 2017-06-27
US20160251324A1 (en) 2016-09-01
PT2300462E (pt) 2014-08-05
ZA201007719B (en) 2011-07-27
KR20110020795A (ko) 2011-03-03

Similar Documents

Publication Publication Date Title
UY31868A (es) Derivados de urea macrocíclicos y derivados de sulfamida como inhibidores de tafia
BRPI0510159A (pt) derivados de imidazol como inibidores de tafia
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CO6390069A2 (es) Compuestos de piridina sustituida unida por puente a un heterociclo, como inhibidores de la vía de señalización hedgehog.
GT200900186A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CR20130024A (es) Compuestos heterocíclicos fusionados
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
CR20110103A (es) Heteroarilos sustituidos
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
UY32168A (es) Nuevas composiciones de compuestos heterociclicos nitrogenados antibacterianos con otros compuestos antibacterianos y su utilización como medicamentos
CR20140367A (es) Inhibidores de iap
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
CY1116384T1 (el) Παραγωγα σουλφαμιδιου ως αναστολεις tafia
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
GT201300041A (es) Composicion fungicida sinergista
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico
NI201000139A (es) ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSAL If Y DE UN BETA-BLOQUEANTE
BR112016002027A2 (pt) derivados de 2-benzoilaminobenzamida como inibidores de bcl-3
UY30760A1 (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia
DOP2007000142A (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181030